| Literature DB >> 24188960 |
Pubudu M Peiris1, Randall Toy2, Aaron Abramowski3, Pete Vicente2, Samantha Tucci2, Lisa Bauer4, Aaron Mayer2, Morgan Tam2, Elizabeth Doolittle2, Jenna Pansky3, Emily Tran2, Dishen Lin2, William P Schiemann5, Ketan B Ghaghada6, Mark A Griswold7, Efstathios Karathanasis8.
Abstract
While potent cytotoxic agents are available to oncologists, the clinical utility of these agents is limited due to their non-specific distribution in the body and toxicity to normal tissues leading to use of suboptimal doses for eradication of metastatic disease. Furthermore, treatment of micrometastases is impeded by several biobarriers, including their small size and high dispersion to organs, making them nearly inaccessible to drugs. To circumvent these limitations in treating metastatic disease, we developed a multicomponent, flexible chain-like nanoparticle (termed nanochain) that possesses a unique ability to gain access to and be deposited at micrometastatic sites. Moreover, coupling nanochain particles to radiofrequency (RF)-triggered cargo delivery facilitated widespread delivery of drug into hard-to-reach cancer cells. Collectively, these features synergistically facilitate effective treatment and ultimately eradication of micrometastatic disease using a low dose of a cytotoxic drug.Entities:
Keywords: Cancer metastasis; Chain-like nanoparticle; Nanochains; Radiofrequency-triggered drug release; Targeting
Mesh:
Substances:
Year: 2013 PMID: 24188960 PMCID: PMC3873646 DOI: 10.1016/j.jconrel.2013.10.031
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776